Candel Therapeutics, Inc.
- CADL
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Viral Therapy
$8.21
Today +0.24%Quote Oct 19, 2026, 08:00 PM UTC
−24.33%over the last month
Max drawdown −30.9%From 1-month high −30.7%3 months −19.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
55
Market value
$628.2M
Quote Oct 19
Floor
$8.02
2.3% below price
Resistance
$8.83
7.6% above price
Price vs analyst targets
10 analysts
Lowest target
$22.00Highest target
$23.00
$22.00Highest target
$23.00
- Price $8.21
- Average target $22.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 174% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CADLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free